254 related articles for article (PubMed ID: 21169407)
1. Using a stem cell-based signature to guide therapeutic selection in cancer.
Shats I; Gatza ML; Chang JT; Mori S; Wang J; Rich J; Nevins JR
Cancer Res; 2011 Mar; 71(5):1772-80. PubMed ID: 21169407
[TBL] [Abstract][Full Text] [Related]
2. Identification and clinical validation of a multigene assay that interrogates the biology of cancer stem cells and predicts metastasis in breast cancer: A retrospective consecutive study.
Pece S; Disalvatore D; Tosoni D; Vecchi M; Confalonieri S; Bertalot G; Viale G; Colleoni M; Veronesi P; Galimberti V; Di Fiore PP
EBioMedicine; 2019 Apr; 42():352-362. PubMed ID: 30846393
[TBL] [Abstract][Full Text] [Related]
3. Expression Profiling of Clinical Specimens Supports the Existence of Neural Progenitor-Like Stem Cells in Basal Breast Cancers.
Panaccione A; Guo Y; Yarbrough WG; Ivanov SV
Clin Breast Cancer; 2017 Jul; 17(4):298-306.e7. PubMed ID: 28216417
[TBL] [Abstract][Full Text] [Related]
4. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer.
Glinsky GV; Berezovska O; Glinskii AB
J Clin Invest; 2005 Jun; 115(6):1503-21. PubMed ID: 15931389
[TBL] [Abstract][Full Text] [Related]
5. First-in-class candidate therapeutics that target mitochondria and effectively prevent cancer cell metastasis: mitoriboscins and TPP compounds.
Ózsvári B; Sotgia F; Lisanti MP
Aging (Albany NY); 2020 May; 12(11):10162-10179. PubMed ID: 32452826
[TBL] [Abstract][Full Text] [Related]
6. BR-BCSC Signature: The Cancer Stem Cell Profile Enriched in Brain Metastases that Predicts a Worse Prognosis in Lymph Node-Positive Breast Cancer.
Dionísio MR; Vieira AF; Carvalho R; Conde I; Oliveira M; Gomes M; Pinto MT; Pereira P; Pimentel J; Souza C; Marques MMC; Duval da Silva V; Barroso A; Preto D; Cameselle-Teijeiro JF; Schmitt F; Ribeiro AS; Paredes J
Cells; 2020 Nov; 9(11):. PubMed ID: 33182375
[TBL] [Abstract][Full Text] [Related]
7. Single cell genomics reveals activation signatures of endogenous SCAR's networks in aneuploid human embryos and clinically intractable malignant tumors.
Glinsky GV
Cancer Lett; 2016 Oct; 381(1):176-93. PubMed ID: 27497790
[TBL] [Abstract][Full Text] [Related]
8. Co-expression modules identified from published immune signatures reveal five distinct immune subtypes in breast cancer.
Amara D; Wolf DM; van 't Veer L; Esserman L; Campbell M; Yau C
Breast Cancer Res Treat; 2017 Jan; 161(1):41-50. PubMed ID: 27815749
[TBL] [Abstract][Full Text] [Related]
9. A qualitative transcriptional signature to reclassify histological grade of ER-positive breast cancer patients.
Li J; Jiang W; Liang Q; Liu G; Dai Y; Zheng H; Yang J; Cai H; Zheng G
BMC Genomics; 2020 Apr; 21(1):283. PubMed ID: 32252627
[TBL] [Abstract][Full Text] [Related]
10. A favorable role of prolactin in human breast cancer reveals novel pathway-based gene signatures indicative of tumor differentiation and favorable patient outcome.
Hachim IY; Shams A; Lebrun JJ; Ali S
Hum Pathol; 2016 Jul; 53():142-52. PubMed ID: 26980025
[TBL] [Abstract][Full Text] [Related]
11. Tamoxifen therapy benefit predictive signature coupled with prognostic signature of post-operative recurrent risk for early stage ER+ breast cancer.
Cai H; Li X; Li J; Ao L; Yan H; Tong M; Guan Q; Li M; Guo Z
Oncotarget; 2015 Dec; 6(42):44593-608. PubMed ID: 26527319
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic pathway signatures in human cancers as a guide to targeted therapies.
Bild AH; Yao G; Chang JT; Wang Q; Potti A; Chasse D; Joshi MB; Harpole D; Lancaster JM; Berchuck A; Olson JA; Marks JR; Dressman HK; West M; Nevins JR
Nature; 2006 Jan; 439(7074):353-7. PubMed ID: 16273092
[TBL] [Abstract][Full Text] [Related]
13. A specific gene expression signature for visceral organ metastasis in breast cancer.
Savci-Heijink CD; Halfwerk H; Koster J; Horlings HM; van de Vijver MJ
BMC Cancer; 2019 Apr; 19(1):333. PubMed ID: 30961553
[TBL] [Abstract][Full Text] [Related]
14. Impact of in vitro driven expression signatures of CD133 stem cell marker and tumor stroma on clinical outcomes in gastric cancers.
Kim TM; Ko YH; Ha SJ; Lee HH
BMC Cancer; 2019 Feb; 19(1):119. PubMed ID: 30717708
[TBL] [Abstract][Full Text] [Related]
15. Lnc RNA H19 is associated with poor prognosis in breast cancer patients and promotes cancer stemness.
Shima H; Kida K; Adachi S; Yamada A; Sugae S; Narui K; Miyagi Y; Nishi M; Ryo A; Murata S; Taniguchi H; Ichikawa Y; Ishikawa T; Endo I
Breast Cancer Res Treat; 2018 Aug; 170(3):507-516. PubMed ID: 29693231
[TBL] [Abstract][Full Text] [Related]
16. Human germ/stem cell-specific gene TEX19 influences cancer cell proliferation and cancer prognosis.
Planells-Palop V; Hazazi A; Feichtinger J; Jezkova J; Thallinger G; Alsiwiehri NO; Almutairi M; Parry L; Wakeman JA; McFarlane RJ
Mol Cancer; 2017 Apr; 16(1):84. PubMed ID: 28446200
[TBL] [Abstract][Full Text] [Related]
17. Identifying cancer subtypes based on embryonic and hematopoietic stem cell signatures in pan-cancer.
Lei J; Luo J; Liu Q; Wang X
Cell Oncol (Dordr); 2024 Apr; 47(2):587-605. PubMed ID: 37821797
[TBL] [Abstract][Full Text] [Related]
18. Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.
Serrano-Oviedo L; Nuncia-Cantarero M; Morcillo-Garcia S; Nieto-Jimenez C; Burgos M; Corrales-Sanchez V; Perez-Peña J; Győrffy B; Ocaña A; Galán-Moya EM
Cell Oncol (Dordr); 2020 Jun; 43(3):431-444. PubMed ID: 32166583
[TBL] [Abstract][Full Text] [Related]
19. "Stemness" genomics law governs clinical behavior of human cancer: implications for decision making in disease management.
Glinsky GV
J Clin Oncol; 2008 Jun; 26(17):2846-53. PubMed ID: 18539963
[TBL] [Abstract][Full Text] [Related]
20. A gene expression signature that predicts the therapeutic response of the basal-like breast cancer to neoadjuvant chemotherapy.
Lin Y; Lin S; Watson M; Trinkaus KM; Kuo S; Naughton MJ; Weilbaecher K; Fleming TP; Aft RL
Breast Cancer Res Treat; 2010 Oct; 123(3):691-9. PubMed ID: 19967557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
